Biosdue secures over 50% of Snia:
This article was originally published in Clinica
Italian financial company Biosdue, a wholly-owned subsidiary of holding company Bios, has announced that it holds 50.1% of biomedical and chemical group Snia, after launching a bid for full control in February (see Clinica No 984, p 15). Bios already owned a 28.3% majority stake in Snia. The group is expected to focus on its biomedical activities, according to comments made by Emilio Gnutti, head of Bios, in an interview with Italian daily Il Sole 24 Ore. Approximately half of Snia's revenues are generated through its medical technology division.